Keros Therapeutics Inc
KROS
Get informed when a big investor buys or sells
+ FollowMarket Cap$352.94M
Close$
$13.60
21.1% upside
Current Fair Value
21.1% upsideUndervalued by 21.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $352.94 Million |
|---|---|
| Enterprise Value | $111.06 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.34 |
| Beta | 1.01 |
| Outstanding Shares | 19,800,322 |
Return
| Return on Equity | -31.70% |
|---|---|
| Return on Assets | -28.91% |
| Return on Invested Capital | -39.99% |
Valuation & Multiples
| P/E Ratio | -2.98 |
|---|---|
| PEG | 46.08 |
| Price to Sales | - |
| Price to Book Ratio | 0.86 |
| Enterprise Value to Revenue | 7.4 |
| Enterprise Value to EBIT | -1.01 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.14 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-1.34
Average shareholder expectationRevenue Estimate
$828,571
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-0.94
Average shareholder expectationRevenue Estimate
$14.76 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 2.3198▲ 188.20% |
|---|---|
| Total Calls | 88,500▼ 81.81% |
| Total Puts | 205,300▼ 3.62% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 94.73%▲ 40.63% |
|---|---|
| Total Invested | $205.56M▼ 49.88% |
| Investors Holding | 156▼ 16.00% |
ESG Score
No data